• JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
 
  Bookmark and Share
 
 
Doctoral Thesis
DOI
https://doi.org/10.11606/T.17.2021.tde-06122021-142908
Document
Author
Full name
Estevão Tavares de Figueiredo
Institute/School/College
Knowledge Area
Date of Defense
Published
Ribeirão Preto, 2021
Supervisor
Committee
Miranda, Carlos Henrique (President)
Markman Filho, Brivaldo
Nicolau, José Carlos
Schmidt, Andre
Title in Portuguese
Variação da relação monócitos/HDL-colesterol é um preditor de eventos cardiovasculares maiores após síndrome coronariana aguda
Keywords in Portuguese
Angina instável
Doença arterial coronariana
Eventos cardiovasculares maiores
HDL-colesterol
Infarto agudo do miocárdio
Monócitos
Abstract in Portuguese
Introdução: Recentemente emergido como um marcador de um estado pró-aterogênico e pró-inflamatório, a relação do número de monócitos pelo valor do HDL-colesterol (RMH) tem sido relatada como um preditor prognóstico nas doenças cardiovasculares. Objetivo: Avaliar se a variação do RMH obtido durante a hospitalização por um evento de síndrome coronariana aguda (SCA) e repetido ambulatorialmente após dois meses é um melhor preditor de eventos cardiovasculares maiores do que a RMH isolada obtida durante o evento agudo. Material e métodos: Coorte prospectiva que incluiu pacientes admitidos por SCA no período de janeiro de 2019 a março de 2020. O RMH foi quantificado em dois momentos: durante a admissão por SCA (RMH1) e no primeiro retorno ambulatorial (RMH2). A partir destes dois valores, foi quantificada a variação desta relação (ΔRMH). Todos os pacientes foram seguidos prospectivamente por meio de contato telefônico avaliando a ocorrência de eventos cardiovasculares maiores (MACE) conforme padronizado internacionalmente durante 180 dias de seguimento. Resultados: Foram incluídos 191 pacientes nesta investigação. Com base na RMH1 e na RMH2, obtida após 66 dias [intervalo interquartil (IQ) 39 - 93], os indivíduos foram divididos em dois grupos, um com diminuição do ΔRMH < 0 (N=113) e, outro, com aumento do ΔRMH ≥ 0 (N=78). Não foram observadas diferenças estatisticamente significativas entre estes dois grupos. A prevalência de MACE foi maior no grupo ΔRMH ≥ 0 em comparação com grupo ΔRMH <0 (22% vs. 07%); p = 0,003. As curvas de Kaplan-Meier mostram uma maior ocorrência de MACE no grupo ΔRMH ≥ 0 vs. grupo ΔRMH < 0 [Hazard ratio (HR): 3,96; (intervalo de confiança (IC) de 95% 1,74 - 8,99); p = 0,0004. A análise da curva de Característica de Operação do Receptor (ROC) mostrou que o ΔRMH foi um melhor preditor da ocorrência de MACE do que as outras duas relações isoladas, ΔRMH área sob a curva (ASC) ROC de 0,73 (IC95% 0,63 - 0,83) vs. RMH1 ASC de 0,49 (IC95% 0,38 - 0,60) vs. RMH2 ASC de 0,65 (IC95% 0,53 - 0,77), respectivamente, p=0,0009. Conclusão: A ΔRMH é um importante marcador prognóstico após SCA. Esta relação é calculada a partir de exames bioquímicos que já fazem parte da rotina destes pacientes, não trazendo custos adicionais. Este é um marcador que poderá ser utilizado para identificação do risco cardiovascular residual após evento de SCA ajudando a identificar pacientes que, potencialmente, se beneficiariam de intervenções adicionais com medicamentos anti-inflamatórios.
Title in English
Variation in monocyte/HDL-cholesterol ratio is a predictor of major cardiovascular events after acute coronary syndrome
Keywords in English
Acute myocardial infarction
Angina unstable
Coronary artery disease
HDL-cholesterol
Major cardiovascular events
Monocytes
Abstract in English
Introduction: Recently emerged as a marker of a pro-atherogenic and pro-inflammatory state, the relationship between the number of monocytes and the value of HDL-cholesterol (MHR) has been reported as a prognostic predictor in cardiovascular diseases. Objective: To assess whether the variation of MHR obtained during hospitalization due to an acute coronary syndrome (ACS) event and repeated on an outpatient basis after 2 months is a better predictor of major cardiovascular events than the isolated MHR obtained during the acute event. Material and methods: Prospective cohort, which included patients admitted for ACS from January 2019 through March 2020. MHR was quantified in two times: during admission by ACS (MHR1) and on the first outpatient evaluation (MHR2). From these two values, the variation of this relation (ΔMHR) was quantified. All patients were followed prospectively through telephone contact assessing the occurrence of major cardiovascular events (MACE) as internationally standardized during 180 days of follow-up. Results: One hundred ninety one patients were included in this investigation. Based on MHR1 and MHR2, obtained after 66 days [interquartile range (IQR) 39-93], individuals were divided into two groups, one with a decrease in ΔMHR <0 (N = 113), and another with an increase in ΔMHR < 0 (N = 78). There were no statistically significant differences between these two groups. The prevalence of MACE was higher in the ΔMHR ≥ 0 group compared to the ΔMHR < 0 group (22% vs. 07%); p = 0.003. The Kaplan-Meier curves show a higher occurrence of MACE in the group ΔMHR ≥ 0 vs. group ΔMHR <0 [Hazard ratio (HR): 3.96; (95% confidence interval (CI) 1.74 - 8.99)]; p = 0.0004. Analysis of the Receiver Operating Characteristic Curve (ROC) showed that ΔMHR was a better predictor of the occurrence of MACE than the other two isolated relation, ΔMHR with area under curve (AUC) ROC of 0.73 (95%CI 0.63 - 0.83) vs. MHR1 AUC of 0.49 (95%CI 0.38 - 0.60) vs. MHR2 AUC of 0.65 (95%CI 0.53 0.77) respectively, p = 0.0009. Conclusion: ΔMHR is an important prognostic marker after ACS. This relation is calculated based on biochemical tests that are already part of the routine of these patients, without additional financial costs. This is a marker that can be used to identify residual cardiovascular risk after an ACS event helping to identify patients who potentially could have a benefit from additional interventions with anti-inflammatory drugs.
 
WARNING - Viewing this document is conditioned on your acceptance of the following terms of use:
This document is only for private use for research and teaching activities. Reproduction for commercial use is forbidden. This rights cover the whole data about this document as well as its contents. Any uses or copies of this document in whole or in part must include the author's name.
Publishing Date
2022-01-07
 
WARNING: Learn what derived works are clicking here.
All rights of the thesis/dissertation are from the authors
CeTI-SC/STI
Digital Library of Theses and Dissertations of USP. Copyright © 2001-2024. All rights reserved.